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Background: COVID-19 has resulted in the largest pandemic experienced since 1918, accounting for over
2 million deaths globally. Frail and older people are at the highest risk of mortality. The main objective
of the present research was to quantify the impact of clinical frailty scale (CFS) by increasing severity of
frailty and to identify other personal prognostic factors associated with increased mortality from
COVID-19.
Methods: This study offers a contemporary systematic review and meta-analysis to analyse the stratified
mortality risk by increasing CFS sub-categories (13, 45 and 69). Databases searched included
EMBASE, MEDLINE, CAB Abstracts, PsychInfo, and Web of Science with end-search restriction the 18th
December 2020. Publications identified via MedRevix were followed up on the 23rd March 2021 in
peer-reviewed database search, and citations were updated as published. Prospective and retrospective
cohort studies which reported the association between CFS and COVID-19 mortality were included.
Thirty-four studies were eligible for systematic review and seventeen for meta-analysis, with 8187%
(I2) heterogeneity.
Findings: All studies [N: 34] included patients from a hospital setting, comprising a total of 18,042 patients
with mean age 72.8 (Min: 56; Max: 86). The CFS 45 patient group had significantly increased mortality
when compared to patients with CFS 13 [(RE) OR 1.95 (1.32 (95% CI), 2.87 (95% CI)); I2 81%; p = 0.0008]. Fur-
thermore, CFS 69 patient group displayed an even more noticeable mortality increase when compared to
patients with CFS 13 [(RE) OR 3.09 (2.03, 4.71); I2 87%; p<0.0001]. Generic inverse variance analysis of
adjusted hazard ratio among included studies highlighted that CFS (p = 0.0001), male gender (p = 0.0009),
National Early Warning Score (p = 0.0001), Ischaemic Heart Disease (IHD) (p = 0.07), Hypertension (HT)
(p<0.0001), and Chronic Kidney Disease (CKD) (p = 0.0009) were associated with increased COVID-19
mortality.
Interpretation: Our findings suggest a differential stratification of CFS scores in the context of COVID-19 infec-
tion, in which CFS 13 patients may be considered at lower risk, CFS 45 at moderate risk, and CFS 69 at
high risk of mortality regardless of age. Overall, our study not only aims to alert clinicians of the value of CFS
scores, but also highlight the multiple dimensions to consider such as age, gender and co-morbidities, even
among moderately frail patients in relation to COVID-19 mortality.
Funding: None.
© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
COVID-19, a novel coronavirus identified in late 2019, has rapidly
spread across the globe resulting in the largest pandemic experienced
since 1918 [1]. Among the infected patients, up to 20% develop severedisease which requires hospitalisation [2,3]. The association between
frailty and consequently Clinical Frailty Scale (CFS) with COVID-19
mortality has been shown in multiple prospective and retrospective
studies, a finding which has promoted the incorporation of CFS in the
management of COVID-19 patients as suggested by the National
Institute for Heath and Care Excellence (NICE) guidelines, despite
caution as advised by certain studies against CFS overestimation in
COVID-19 prognosis [47]. Frailty prevalence is varied and affects
Research in Context
Evidence before this study
COVID-19 has resulted in the largest pandemic experienced
since 1918, with detrimental effects upon most vulnerable and
frail populations. The association between frailty and conse-
quently CFS with COVID-19 mortality has been shown in multi-
ple prospective and retrospective studies, a finding which has
promoted the incorporation of CFS in the management of
COVID-19 patients as suggested by the NICE guidelines.
Added value of this study
This study offers a contemporary systematic review and meta-
analysis to analysis the stratified mortality risk by increasing
CFS sub-categories (13, 45 and 69).
Implication of all the available evidence
Differential stratification of the CFS scores, in the context of
COVID-19 infection, is proposed in which CFS 13 patients may
be considered at lower risk, CFS 45 at moderate and CFS 69
at high risk of mortality. Overall, our study not only aims to
alert clinicians of the value of CFS scores, but also the multiple
dimensions to consider such as age, gender and co-morbidities,
even among moderately frail patients in relation to COVID-19
mortality.
2 S. Kastora et al. / EClinicalMedicine 36 (2021) 100896approximately 40% of middle-aged to older patients with age com-
monly, but not always, correlating with higher scores in the CFS [8].
To date, a limited number of systematic reviews and even fewer
meta-analyses have confirmed the association between CFS and
patient mortality with inherent limitations originating from the
incorporated studies [7,9]. Nonetheless, until present and to the best
of our knowledge, no study has attempted to correlate increasing
level of CFS scores, in the context of modifiable and non-modifiable
patient factors, with mortality outcomes.
Furthermore, multiple confounding factors have been shown to
worsen COVID-19 prognosis. Common complications include acute
kidney injury (AKI), cardiac injury and sudden cardiac death, whilst
hyperactive delirium complicates the management of two-thirds of
critically ill patients [10,11]. How these variables interplay with the
CFS patient categorisation for poorer or improved COVID-19 out-
comes remains elusive and present a ground for clarification in the
present study.
Overall, our study aims to quantify the impact of CFS by increasing
severity of frailty and to identify other personal prognostic factors
associated with increased mortality from COVID-19 infection.
2. Methods
2.1. Search strategy and selection criteria
A systematic literature review was conducted according to the
guidelines of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) (Fig. 1) [12]. A study protocol was not
registered for the present study.
Independent literature search for relevant studies was performed
up to 18th December 2020 on five databases: EMBASE, MEDLINE,
CAB Abstracts, PsychInfo, and Web of Science. Additional records
were identified through other sources, including SSRNs eLibrary,
Research Square and MedRxiv. The MedRxiv search was simplified
according to database search functionality. Publications identified via
MedRevix were followed up on the 23rd March 2021 in peer-
reviewed database search, and citations were updated as published.The references of the included studies were scrutinized for additional
relevant studies. Search limitations included human participants and
English language articles. The following search term was used in
OVID: (clinical frailty scale OR clinical frailty score OR frail*).mh,tw,
ab,hw,kw. AND (2019 Novel Coronavirus Disease OR 2019 Novel
Coronavirus Infection OR 2019-nCoV Disease OR 2019-nCoV Infection
OR COVID-19 Pandemic OR COVID-19 Pandemics OR COVID-19 Virus
Disease OR COVID-19 Virus Infection OR COVID19 OR Coronavirus
Disease 2019 OR Coronavirus Disease-19 OR SARS Coronavirus 2
Infection OR SARS-CoV-2 Infection).mp. limit to (English language
and humans). The same search strategy was adapted for the remain-
ing databases.
Prospective and retrospective cohort studies were included exam-
ining COVID-19 mortality in the context of CFS scale (Table S1).
Restrictions included English language and human. Restrictions were
not applied to participant age, gender or ethnicity. Full-text exclusion
criteria were: Different frailty measurement tool other than the CFS
[Hospital Frailty Risk Score (HFRS); Fried Frailty Scale (FRIED)];
including only deceased patients; not reporting specific mortality
numbers; and CFS and caregiver association rather than mortality.
Excluded studies and justifications are recorded in Table S3.
After removing duplicates, citations were screened by title and
abstract, then full texts were appraised to determine their eligibility
by three authors (GK, SK, SP) (Fig. 1). Three authors (GK, SK, SP) inde-
pendently conducted the abstract and full text screening. Disagree-
ments were resolved by a consensus meeting. Peer-reviewed full-
text papers that reported mortality outcome were selected.
Data from each article was extracted by two authors (GK, SP) and
validated independently by a third researcher (SK): (1) Total number
of participants, type of study, setting of study (hospital), length of
hospital stay, discharge, Clinical Frailty Scale score, patient character-
istics: age, gender, method of COVID-19 diagnosis, co-morbidities
(respiratory, cardiovascular (CVS), chronic kidney disease (CKD), can-
cer, diabetes mellitus, delirium development %, National Early Warn-
ing Score (NEWS). More specifically, the term “cardiovascular co-
morbidities” included hypertension, heart failure (HF) dyslipidaemia,
previous cerebrovascular accident, ischaemic heart disease (IHD),
myocardial infarction. The term “respiratory co-morbidities’ included
chronic obstructive pulmonary disease (COPD), asthma and intersti-
tial lung fibrosis. Type 1 and type 2 diabetes mellitus were analysed
together and mentioned with the umbrella term “Diabetes”. CKD and
AKI represented two different entities and analysed separately. The
CKD term did not include AKI patients as this parameter could not
confidently be identified as an independent factor to the active
COVID-19 infection. Patients diagnosed with solid tumours or haema-
tological malignancies were grouped together under the umbrella
term “Cancer”.
Quality of the included studies were assessed by three indepen-
dent reviewers (GK, SK, SP) using the Newcastle-Ottawa Scale (NOS)
for observational studies [13]. Bias analysis was conducted via the
Cochrane recommended tool (RevMan V. 5.4). Studies were consid-
ered to be high quality if they had a NOS score 6. Adequate follow-
up was considered to be  30 days (Table S2).
2.2. Data analysis
Clinicalstudy, context and design, were compared and those in
which, populations were considered suitably homogeneous, were
pooled [14]. The meta-analysis was conducted by computing the
odds ratio (OR), random effects (RE) from the original data using the
DerSimonian-Laird method with Review Manager (RevMan) v5.4
software using a random-effect model. Statistical heterogeneity was
quantified using I2 statistics and Cochrane Q tests.
The primary outcome of this study was to identify COVID-19 asso-
ciated mortality among CFS groups. Confounding factors of increased
mortality were assessed using generic inverse variance model
Fig. 1. Prisma 2009 Flow Diagram. Search strategy included and excluded studies.
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mary outcome. Variables assessed included age (continuous variable),
gender (categorical variable), smoking status (categorical), BMI (con-
tinuous), NEWS (categorical), active cancer diagnosis (categorical),
respiratory conditions (categorical), diabetes (categorical), hyperten-
sion (categorical), IHD (categorical), CKD (categorical), AKI (categori-
cal), and delirium (categorical). Both crude hazard ratio (HR) and
adjusted HR were presented with associated 95% Confidence Inter-
vals (CI). HR (95% CI) per Model, where Model 1 (Adjusted for Age,
Gender), Model 2 (adjusted for Age, Gender, Co-morbidities), and
Model 3 (Adjusted for Age; Gender; Co-morbidities; Biochemical
findings) are depicted in the associated tables to explore heterogene-
ity. Collective adjusted HR were used for forest plots, unstratified for
adjusted parameters.
Asymmetry was assessed by funnel plot, and asymmetry was
assessed formally by rank correlation test (Begg's test; RevMan V.5.4) [15]. Sensitivity analyses were conducted to assess the impact of
individual potential confounding variables. Publication bias was
assessed visually by funnel plot, and asymmetry was assessed for-
mally by rank correlation test (Begg's test) [15].
2.3. Role of the funding source
There was no funding source for this study. All authors confirm
that they had full access to the dataset of the study and accept
responsibility to submit for publication.
3. Results
Following the PRISMA guidelines on systematic review search, we
identified 64 studies eligible for full-text screening. Full-text screen-
ing excluded 30 studies (Table S3, companion file). A total of 34
Fig. 2. Odds associated with increased frailty (CFS 45 vs. CFS 13). DerSimonian and Laird statistical method with odds ratio as output only for included observational studies.
Forrest plot of included observational studies of the meta-analysis (patients with CFS 45 COVID-19 mortality vs. patients with CFS 13 COVID-19 mortality) representing respec-
tive reduction or increase in mortality in the frailest population, is shown in Fig. S3, random effects odds ratio 1.95 (1.32,2.87; I2 81%). Forrest and associated funnel plots (Fig. S3)
were generated with Review Manager V. 5.4 Cochrane Tool for meta-analysis.
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tematic review while 17 were included in the meta-analysis
[4,5,3347] (Fig. 1; Table S1). Given that all available studies examin-
ing the CFS under the prism of COVID-19 mortality were observa-
tional, we employed the NOS for quality assessment [13]. Twenty-
two studies were graded as good, two as fair and ten studies as poor
according to independent grading as per NOS selection, comparabil-
ity and outcome parameters (Table S2).
All studies [N:34] included patients from a hospital setting
[4,5,1647], comprising a total of 18,042 patients with mean age
72.8 (Min: 56; Max: 86). Over half (57.2%) [10,320/18,042]
[4,5,1647] of the COVID-19-positive patients were male (Fig. S1C),
30.6% [4691/15,430] [4,5,1624,27,2933,3536,38,40,42,4547] of
the patients suffered from cardiovascular co-morbidities, 12.19%
[1556/12,761] [4,1619,21,2324,27,2931,33,3536,38,40,42,
4547] had a pre-existing respiratory co-morbidity, 22.6% [3487/
15,430] [4,5,1620,24,27,2933,3536,38,40,42,4547] were dia-
betic, cancer patients comprised a total of 7.8% [895/11,469]
[4,16,18,23,24,27,2931,33,35,38,46,47] of the analysed patient pop-
ulation, whilst 12.4% [1329/10,716] [5,16,1819,2324,27,
3031,33,35,38,40,46] of patients were suffering from a CKD (Fig.
S1C). The overall mortality% across studies was 31.1% (SD: 14.1)
[5611/18,042] [4,5,1647] (Fig. S1C). A mean of 32.7% (SD: 35.5)
[1546/4727] [4,1618,20,21,23,30,31,33,35,38,46] required intuba-
tion and mean overall admission to Intensive Care Unit (ICU) was
11.0% (SD: 6.3) [586/5330] [16,17,22,25,29,33,38,39,42,44,46] (Fig.
S1C). Length of hospital stay mean was 12.2 days (SD: 13.3)
[18,19,21,24-26,30,34,38,39,41,43,44] (Fig. S1C). A 60.3% (SD: 16.8)
[8807/14,606] [4,5,17,1923,25,27,28,32,33,35,36,38-40,42,46,47] of
patients were discharged within the timeline of the included studies
(Fig. S1C). Interestingly, almost a quarter of patients, 24.1% (SD: 14.5)
[1742/7226] [22,24,25,27,28,36,38,41,47] either presented or devel-
oped delirium during their hospital admission (Fig. S1C). Observed I2
was significantly decreased with sensitivity analysis as per NOS scale
grading (Fig. S4).
Of the thirty-four studies, seventeen [4,5,3347] were included in
the meta-analysis, whilst a total of seventeen studies were excluded
because mortality was either not reported in CFS increments or crude
patient numbers were unavailable (Table S4). Patient groups werestratified according to their CFS hierarchical scale upon hospital
admission. CFS numerically ranks frailty taking into account patient
co-morbidities and functional status spanning from 1 to 9. Patients
scoring 1 are considered to be very fit, 2 - well, 3 - managing well, 4 -
vulnerable, 5 - mildly frail, 6 - moderately frail, 7 - severely frail, 8 -
very severely frail, and 9 - terminally ill [48]. For the purposes of this
meta-analysis, we stratified patients with CFS 13,CFS 45, and CFS
69, and assessed their respective OR of mortality between CFS sub-
groups (Fig. 2, Fig. 3, Fig. S3). Control group was set as the CFS 13.
We found that the CFS 45 patient group had significantly increased
mortality when compared to patients with CFS 13 [(RE) OR 1.95
(1.32,2.87); I2 81%; p = 0.0008]. Furthermore, mortality in the CFS
69 patient group was noticeably increased when compared to
patients with CFS 13 [(RE) OR 3.09 (2.03, 4.71); I2 87%; p<0.0001].
Comparison between the CFS 45 vs. CFS 69 also returned signifi-
cant results [(RE) OR 1.51 (1.23, 1.84)] (Fig. S2). These results
remained significant even when included studies were restricted to
only those with standard error (SE) [log (OR)] <0.6 and mapped to
NOS scale (Fig. S4) [49].
Lastly, we sought to identify confounding factors that may corre-
late with COVID-19 mortality across all included studies (Fig. S5, Fig.
S6). Overall, CFS, male gender, NEWS, Diabetes, CVS co-morbidities
(including Hypertension and IHD) and CKD were associated with
increased COVID-19 mortality among CFS groups in unadjusted HR
(Fig. S5) and adjusted HR analysis as reported in each study (Fig. S6).
CFS, male gender and increased NEWS were statistically significant,
predictors of poor prognosis in the adjusted for age, gender, co-mor-
bidities and biochemical findings HR, IVR analysis for COVID-19 mor-
tality across studies (Model 3; Fig. S6). These findings highlight the
multitude of dimensions at interplay dictating COVID-19 mortality
along with the CFS scale.
4. Discussion
Globally, over 100 million confirmed cases of COVID-19 have been
reported with more than 2 million deaths. As we strive to improve
patient management, achieve population vaccination and maintain
distancing measures, the elderly population continues to be sub-
jected to the highest mortality among all infected patient groups,
Fig. 3. Odds associated with increased frailty (CFS 69 vs. CFS 13). DerSimonian and Laird statistical method with odds ratio as output only for included observational studies.
Forrest plot of included observational studies of the meta-analysis (patients with CFS 69 COVID-19 mortality vs. patients with CFS 13 COVID-19 mortality), representing respec-
tive reduction or increase in mortality in the frailest population, random effects odds ratio 3.09 (2.03, 4.71); I2 87%. Forrest and associated funnel plots (Fig. S3) were generated with
Review Manager V. 5.4 Cochrane Tool for meta-analysis.
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[9] have been conducted with smaller numbers of included studies,
given the rapidly evolving literature on the subject we have
attempted to correlate not only the entirety of the CFS scale with
mortality outcomes but also CFS-specific stratified patient groups, by
incorporating a total of 34 studies, 17 of which were included in the
meta-analysis.
As expected, the difference among the CFS 13 AND CFS 69
patient groups were very noticeable with favoured survival in the
CFS 13 group [(RE) OR 3.09 (2.03, 4.71); p<0.0001]. Equally, signifi-
cant differences were also observed between fit (CFS 13) and vul-
nerable patients (CFS 45), with [(RE) OR 1.95 (1.32, 2.87); p
<0.0008]. This analysis indicated an almost stepwise increase in mor-
tality as we moved up the scale of frailty. Given this finding, we can
hypothesise that even subtle changes in the CFS scale can signifi-
cantly worsen patient outcomes. Previous work has suggested a 12%
incremental increase of mortality per 1-point in the CFS scale in a lin-
ear fashion, a finding which was not consistent with our findings. We
identified variable increase of mortality between single CFS scores
(Fig. S7), whilst linear increase was identified between CFS groups
(13 vs. 45; vs. 69) rather than single CFS groups. Furthermore,
we have identified modifiable and non-modifiable variables that
associate with poorer outcomes for COVID-19 mortality across all CFS
groups. Whilst age, male gender and cardiovascular co-morbidities
have been previously associated with worse prognosis [5153], this
work has also identified CKD as another poor prognosticator.
It is now established that COVID-19 disproportionately affects
patients with pre-existing comorbidities [54]. The National Kidney
Foundation has already advised caution for patients of CKD stage 3
and above or those receiving dialysis. The molecular pathway
through which COVID-19 infection worsens CKD pathophysiology
remains elusive, nonetheless. Molecular work has indicated that
whilst the mechanism may be multifactorial, the angioten-
sinconverting enzyme 2 (ACE2) pathway may be under increased
scrutiny [55]. Further factors that may worsen outcomes of CKD
patients may be the extensive albuminuria and proteinuria as
observed in COVID19 hospitalized patients, which on top of pre-
existing CKD may induce an acute-on-chronic kidney injury [56]. Pre-
vious work has also suggested that patients with pre-existing cardio-
vascular disease and overall decreasing CVS integrity are more proneto COVID-19 complications and poorer survival outcomes [52]. Tar-
geted cardiac assessment is currently recommended in patients with
new-onset HF (including left HF and acute cor pulmonale), unex-
plained cardiac arrhythmias, or ECG changes (more specifically ST
elevation) as well as pre-existing CVS co-morbidities [51]. The patho-
physiology of acute on chronic cardiovascular injury upon chronic
infection is also, as expected, multifactorial, mainly disseminating via
direct viral invasion of the myocardium through ACE2 receptor and
Transmembrane protease serine 2 (TMPRSS2) protease and Angio-
tensin IImediated inflammatory response [57,58].
Other positively associated factors with COVID-19 mortality
include delirium and active cancer - albeit a lack of statistical signifi-
cance. Delirium has been shown to be noticeably prevalent in elderly
and potentially more frail adults, although it is not exclusive to
increased age, and high delirium rates have been observed amongst
all critically ill patients [11]. Whilst delirium cannot be considered an
independent confounder of COVID-19 induced mortality, its synergis-
tic association is evident despite being elusive mechanistically. More
research is required in order to comprehend why patients with
hyperactive delirium are more prone to increased COVID-19 mortal-
ity. Furthermore, our data concur with previous literature associating
male gender and NEWS with poorer COVID-19 outcomes in the
elderly [5059]. Of note previous pioneering work in the acute set-
ting, prior to the COVID-19 pandemic, had already indicated that
higher NEWS and CFS correlate, predicting illness severity, mortality
and readmission rate, in the frailer population [59].
While the molecular background rendering male patients more
susceptible to severe COVID-19 complications and death remains
obscure, studies have suggested that higher ACE-2 expression, sex-
immunological differences (e.g. interleukin (IL) IL-4, IL-10, and the IL-
12 expression levels), lifestyle factors, as well as overall attitudes
towards the COVID-19 pandemic, play pivotal roles in the observed
outcomes [6064]. Lastly, we identified increased intubation % to be
associated with mortality, a finding that should be taken into context;
only patients most in need of mechanical ventilation due to COVID-
19 infection receive this. Mortality among patients requiring invasive
ventilation, regardless of age group, has been shown to be as high as
42.7% [65]. Considering that older age groups, which comparatively
suffer from a higher number of pre-existing co-morbidities [54], it is
not surprising that intubation requirement % was found to be
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studies. Overall, our study, in alignment with previous research, not
only highlights the importance of CFS scale in correlation with
COVID-19 mortality prediction, but also emphasises the multiple
demographic and physiological variables at interplay that may
impact on COVID-19 mortality prediction. Consequently, as in the
context of other medical conditions, especially in the geriatric popu-
lation, a comprehensive geriatric assessment is not only desired but
necessary to identify patient medical, psychosocial, and functional
limitations that impact patient outcomes in the context of COVID-19
infection.
Our study suffers from the inherent limitations of the contempo-
rarily published observational studies and the evident lack of rando-
mised control trials (RCT). Whilst RCT studies are extremely difficult
to be formulated amidst the COVID-19 pandemic, their outcomes
would be extremely valuable in on-going patient care. Additionally,
small patient numbers and variable CFS and co-morbidities reporting
across studies increased overall reporting and selection bias amidst
included studies. Whilst taking into account the inherent limitations
of a meta-analysis without included randomised controlled trials, our
systematic review and meta-analysis has been conducted according
to the Cochrane standards to provide rigorous results under statisti-
cian guidance. We have identified and addressed sources of heteroge-
neity by NOS subgrouping, sensitivity and IVR analysis. By preserving
the integrity of frailty assessment across studies, by selecting only
those reporting on CFS system, we were able to make comparisons
across studies [7]. Whilst previous work has highlighted the linearity
of CFS and COVID-19 mortality in dose-response fashion [79], the
present work is the first to provide scaled CFS score association with
mortality risk in the context of patient modifiable and non-modifi-
able confounding factors. These include gender, cardiovascular, renal
and endocrine co-morbidities as well as acute deterioration indica-
tors such as the NEWS and delirium development.
In terms of clinical intuition, it is expected that CFS 79 corre-
sponds with an increased risk of mortality. Whilst this holds true,
this work underlines that even patients with lower CFS scores (e.g.,
45) display significant mortality risks in comparison to the CFS 1-3
groups. This finding should uniformly change the way we view CFS
amidst the COVID pandemic and encourage clinicians to use more
comprehensive patient assessment and management - even when
patients are considered to be vulnerable to frailty but are not yet frail.
Our findings suggest a differential stratification of the CFS scores, in
the context of COVID-19 infection, in which CFS 13 patients may be
considered at lower risk, CFS 45 at moderate risk and CFS 69 at
high risk of mortality. Patients’ CFS score should be assessed within
the context of a comprehensive clinical assessment, taking into
account demographic and physiological variables, to efficiently pre-
dict COVID-19 mortality and act proactively towards improving
patient outcomes.
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